Charles River Laboratories International, Inc. (CRL)
CRL's Q3 Earnings Top Estimates, Revenues Decline Y/Y, Stock Falls
Charles River beats Q3 profit and revenue forecasts but posts year-over-year declines and narrows its 2025 outlook.
Charles River Laboratories (CRL) Q3 Earnings and Revenues Surpass Estimates
Charles River Laboratories (CRL) came out with quarterly earnings of $2.43 per share, beating the Zacks Consensus Estimate of $2.32 per share. This compares to earnings of $2.59 per share a year ago.
Charles River Laboratories (CRL) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
Charles River (CRL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's How Charles River Stock Is Placed Ahead of Q3 Earnings
CRL heads into Q3 earnings with steady RMS growth but faces DSA headwinds from tight biotech budgets.
Will Charles River (CRL) Beat Estimates Again in Its Next Earnings Report?
Charles River (CRL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
3 Medical Service Industry Stocks Poised to Counter Workforce Issues
Here are three resilient medical services stocks, Labcorp, Charles River Laboratories and Teladoc, that are poised to outperform amid staffing shortages and digital healthcare growth.
Charles River Laboratories International, Inc. (CRL) Presents At Baird 2025 Global Healthcare Conference (Transcript)
Charles River Laboratories International, Inc. (NYSE:CRL ) Baird 2025 Global Healthcare Conference September 10, 2025 9:40 AM EDT Company Participants James Foster - Chairman, President & CEO Conference Call Participants Eric Coldwell - Robert W. Baird & Co. Incorporated, Research Division Presentation Eric Coldwell Senior Research Analyst Good morning, everyone.
Is it the Right Time to Add CRL Stock to Your Portfolio Now?
Charles River's DSA growth, acquisitions and collaborations support momentum, but forex and macro headwinds weigh on its outlook.
Charles River Stock May Benefit From Joining EASYGEN Consortium
CRL joins EASYGEN to speed CAR-T therapy delivery, which may boost patient access and investor sentiment.
Charles River Laboratories International, Inc. (CRL) Q2 2025 Earnings Call Transcript
Charles River Laboratories International, Inc. (NYSE:CRL ) Q2 2025 Earnings Conference Call August 6, 2025 9:00 AM ET Company Participants Flavia H. Pease - Corporate Executive VP & CFO James C.
Charles River: Margin Fears Outweigh Solid Q2
Charles River Laboratories posted a strong Q2 beat, but results were boosted by one-time items and cost cuts that may not be sustainable. Ongoing risks include regulatory pressure to phase out animal testing and weak organic revenue growth, especially in the Discovery and Safety Assessment segment. Management raised full-year guidance, but H2 faces margin and revenue headwinds; Q3 EPS is expected to decline sequentially.
Charles River (CRL) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Charles River (CRL) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
